Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Early Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (100.0%)Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Early Phase 1
Active, not recruiting
- Conditions
- Influenza A
- Interventions
- Biological: Influenza Fluzone vaccine
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- La Jolla Institute for Immunology
- Target Recruit Count
- 23
- Registration Number
- NCT06567860
- Locations
- 🇺🇸
La Jolla Institute for Immunology, La Jolla, California, United States
News
Kyowa Kirin to Present Phase 3 Rocatinlimab Results for Atopic Dermatitis at EADV 2025
Kyowa Kirin will present results from the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational anti-OX40 monoclonal antibody for moderate-to-severe atopic dermatitis, at the EADV 2025 Annual Meeting in Paris.
Kyowa Kirin and La Jolla Institute Extend 35-Year Research Alliance with Focus on Cell and Gene Therapies
The 35-year partnership between Kyowa Kirin and La Jolla Institute for Immunology has been renewed for three more years, representing one of the longest-standing industry-academic collaborations in drug discovery.